

1 **JAC-2017-1701 Revised Manuscript 1**

2

3 **Antimicrobial Susceptibility Testing of Invasive Isolates of *Streptococcus pneumoniae* from**
4 **Canadian patients: The SAVE Study, 2011-2015**

5

6 James A. Karlowsky^{1,2}, Heather J. Adam^{1,2}, Alyssa R. Golden¹, Melanie R. Baxter¹, Kim A.

7 Nichol², Irene Martin³, Walter Demczuk³, Michael R. Mulvey^{1,3}, Matthew W. Gilmour^{1,3}, Daryl

8 J. Hoban^{1,2}, George G. Zhanel^{1*}, on behalf of the Canadian Antimicrobial Resistance Alliance

9 (CARA)[†]

10

11 ¹*Department of Medical Microbiology, Max Rady College of Medicine, University of Manitoba,*

12 *Room 543 - 745 Bannatyne Avenue, Winnipeg, Manitoba, R3E 0J9, Canada;*

13 ²*Clinical Microbiology, Diagnostic Services Manitoba, MS673-820 Sherbrook Street, Winnipeg,*

14 *Manitoba, R3A 1R9, Canada;*

15 ³*National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street,*

16 *Winnipeg, Manitoba, R3E 3M4, Canada*

17

18 **Intended category:** Original article

19 **Running title:** AST of Invasive Pneumococci in Canada; The SAVE Study, 2011-2015

20

21 [†] Member laboratories are listed in the Acknowledgements section.

22

23 **Corresponding author:** Mailing address: Dr. George G. Zhanel, Department of Clinical
24 Microbiology, Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba,
25 Canada, R3A 1R9. Telephone: 204-787-4902; Fax: 204-787-4699; Email: ggzhanel@pcs.mb.ca.

26 **Synopsis**

27 **Objectives:** To assess antimicrobial susceptibility for 14 agents tested against 6001 invasive
28 isolates of *Streptococcus pneumoniae* cultured from invasive patient samples from 2011 to 2015
29 as a part of the annual SAVE study.

30 **Methods:** Isolates of *S. pneumoniae* were tested using the standard CLSI broth microdilution
31 method (M07-A10, 2015) with MICs interpreted by CLSI M100 27th Edition (2017) MIC
32 breakpoints.

33 **Results:** From 2011 to 2015, small but significant increases ($P < 0.05$) in percent susceptibility
34 for penicillin (interpreted by all three CLSI MIC breakpoint criteria) (1.7 – 3.2%), clindamycin
35 (3.1%) and ceftriaxone (interpreted by non-meningitis and meningitis CLSI MIC breakpoint
36 criteria) (1.1 – 1.5%) were observed. Susceptibility rates for clarithromycin and other commonly
37 tested antimicrobial agents remained unchanged ($P > 0.05$) over the five-year period. Isolates
38 with a MDR phenotype (resistance to three or more antimicrobial agent classes) decreased
39 significantly ($P < 0.001$) from 8.5% in 2011 to 5.6% in 2015. Antimicrobial susceptibility rates
40 were not generally associated ($P > 0.05$) with patient gender (exception: clarithromycin) but were
41 associated ($P < 0.05$) with patient age (chloramphenicol and clindamycin) or specimen source
42 (penicillin, doxycycline, trimethoprim/sulfamethoxazole and clindamycin), as well as geographic
43 location in Canada and concurrent resistance to penicillin or clarithromycin.

44 **Conclusions:** The *in vitro* susceptibility of invasive isolates of *S. pneumoniae* in Canada
45 increased to penicillin, clindamycin and ceftriaxone from 2011 to 2015 coincident with a
46 significant decrease in MDR phenotypes.

47 **Introduction**

48 *Streptococcus pneumoniae* is a leading cause of both invasive (e.g., bacteremia, meningitis) and
49 non-invasive (e.g., pneumonia, otitis media) infections.¹ Invasive pneumococcal disease (IPD)
50 produces substantial patient morbidity and mortality, particularly among the very young (<5
51 years), the elderly (≥65 years) and immunocompromised individuals. In addition to the
52 aforementioned risk factors for IPD, both carriage of, and infection with, antimicrobial-resistant
53 *S. pneumoniae* is associated with previous antimicrobial use, institutionalization, and community
54 or household exposure to antimicrobial-resistant isolates.² Resistance arising following previous
55 antimicrobial use is more dependent on the time elapsed since the last antimicrobial exposure
56 rather than on the duration of therapy; the association between elapsed time and resistance was
57 stronger for macrolides than other antimicrobial classes.²

58 In patients with pneumococcal infection, particularly IPD, adequate antimicrobial therapy
59 reduces morbidity and mortality, particularly when administered early in the course of disease.²
60 The success of empiric antimicrobial therapy is continuously challenged by the threat of
61 increasing antimicrobial resistance, serious adverse events, and collateral damage to patients'
62 colonizing flora. The development of new antimicrobial agents with novel mechanisms of action
63 and attempting to minimize the use of currently available agents through antimicrobial
64 stewardship are two important strategies intended to subvert the spread of antimicrobial
65 resistance.

66 Vaccination is a proven means of reducing the incidence of IPD and antimicrobial
67 resistance associated with serotypes included in the vaccine by reducing the transmission of
68 resistant isolates.^{1,3-7} In June 2001, the 7-valent (4, 6B, 9V, 14, 18C, 19F, 23F) conjugate
69 vaccine (PCV-7) was licensed for use in Canada and universal infant (children <2 years of age)

70 PCV-7 immunization programs were introduced in all Canadian provinces and territories
71 between 2002 and 2006.¹ As anticipated, the Canadian Immunization Monitoring Program,
72 Active (IMPACT) reported a significant decrease in the number of cases of IPD between 2000
73 and 2007 (a 48% decrease overall and 56% in children <5 years old)¹ with the greatest decreases
74 in incidence of IPD, and rates of antimicrobial resistance, occurring in children <2 years of
75 age.^{1,3,4} At the same time, increases in non-vaccine serotypes (e.g., 19A) as causes of IPD and
76 sources of antimicrobial resistance were observed and offset some of the reductions in PCV-7
77 serotypes.^{1,5} Bettinger *et al.* reported that although the absolute number of reported IPD cases
78 caused by serotypes in PCV-7 decreased 87.5%, overall the proportion of penicillin-resistant
79 isolates remained unchanged at 17% and cefotaxime/ceftriaxone resistance remained unchanged
80 at 2% annually.¹ Subsequently, in 2010, a 13-valent polyvalent conjugate vaccine (PCV-13)
81 targeting additional serotypes (1, 3, 5, 6A, 7F, 19A) was introduced in Canada and by mid-2011,
82 all Canadian provinces and territories had incorporated PCV-13 into their routine immunization
83 schedule. Prior to PCV-13 introduction in Canada, Adam *et al.* reported that 54.3% of
84 circulating serotypes causing IPD in 2007-2009 would be covered by PCV-13.⁶ Demczuk *et al.*
85 later reported that from 2010 to 2014, PCV-13 serotypes declined in Canada, overall, from 55%
86 of the isolates in 2010 to 43% in 2012 to 31% in 2014; by patient age, PCV serotype reductions
87 were from 54 to 43% for children aged ≥ 5 years, from 66 to 41% for children <5 years old and
88 from 63 to 42% for children aged <2 years.^{7,8} The rate of decrease in IPD serotypes in children
89 following the introduction of PCV-13 was less dramatic than that observed for PCV-7 over a
90 comparable time period.⁷ Serotype 22F has been the most common replacement serotype
91 following use of PCV-13, increasing from 7% to 11%.⁸ Similar results have been observed in
92 the United States for children <5 years of age where the use of PCV-7 and PCV-13 has also been

93 widespread; they observed a 90% decline in IPD in children <5 years of age and a 50% decline
94 in adults between 1998 and 2015.⁹ As a result of the use of PCV-7 and PCV-13 in Canada, the
95 overall incidence of IPD decreased from 9.8 to 8.9 cases per 100 000 population between 2009
96 and 2014. In 2014 in Canada, rates of IPD were highest in infants <1 year of age (16.9 cases per
97 100 000 population), children 1-4 years of age (11.0 cases per 100 000 population), and in
98 patients 60 years of age and older (21.5 cases per 100 000 population).^{10,11}

99 Despite the availability and use of pneumococcal conjugate vaccines in Canada, invasive
100 infections continue to occur. Therefore, access to current antimicrobial surveillance data such as
101 that generated by the ongoing SAVE study in Canada remains important to clinicians,
102 antimicrobial stewardship programs, infection control practitioners, antimicrobial formulary
103 committees, clinical laboratory scientists, governments, academic scientists involved in drug
104 discovery and the pharmaceutical industry as this data can improve the delivery of effective
105 antimicrobial therapy (reducing discordant empiric therapy that results in increased rates of
106 morbidity and mortality), determine the impact of immunization programs, provide the impetus
107 to revise empiric therapy guidelines and help to prioritize future antimicrobial agent development
108 agendas.² The SAVE study is an annual surveillance program that collects and characterizes
109 invasive isolates of *S. pneumoniae* submitted by select provincial public health and hospital
110 laboratories across Canada. In the current study, invasive isolates of *S. pneumoniae* collected
111 from 2011 to 2015, inclusive, by the SAVE study were tested for their susceptibilities to a panel
112 of 14 antimicrobial agents using the standard CLSI broth microdilution method.^{12,13} Because
113 comparative statistical analyses of factors associated with antimicrobial resistance have not been
114 extensively performed using Canadian pneumococcal isolates, data from the SAVE study were
115 also analyzed to evaluate the activities of several anti-pneumococcal agents on the basis of

116 factors such as patient age, patient gender, isolate specimen source, geographic region and MIC
117 interpretative category for penicillin and clarithromycin.

118

119 **Materials and methods**

120 ***Bacterial isolates***

121 From January 2011 to December 2015, *S. pneumoniae* isolated from sterile body sites by
122 participating Canadian provincial public health and hospital laboratories were forwarded to the
123 Public Health Agency of Canada-National Microbiology Laboratory (PHAC-NML) in Winnipeg,
124 Canada. As part of an ongoing collaboration between the Canadian Antimicrobial Resistance
125 Alliance (CARA) and PHAC-NML, PHAC-NML forwarded their collection of invasive isolates
126 of *S. pneumoniae* eight provincial public health laboratories (Saskatchewan, Manitoba, Ontario,
127 Quebec, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and a portion of
128 isolates collected from New Brunswick) to CARA for antimicrobial susceptibility testing. For
129 the SAVE study, regional analysis were conducted as Western (Saskatchewan and Manitoba,
130 $n=1352$), Central (Ontario and Quebec, $n=4107$) and Eastern (New Brunswick, Nova Scotia,
131 Prince Edward Island, and Newfoundland and Labrador, $n=748$).

132 In total, 6207 invasive isolates of *S. pneumoniae* collected as part of the SAVE study

133 between 2011 and 2015 were forwarded to the CARA for antimicrobial susceptibility testing.

134 Patient gender and age information was available for 5980 (96.3%) and 6072 (97.8%) of the

135 isolates. The annual numbers of isolates were: 1379 isolates from 2011, 1285 from 2012, 1138

136 from 2013, 1210 from 2014, and 1195 from 2015.

137 ***Antimicrobial susceptibility testing***

138 Antimicrobial susceptibility testing was performed in the Department of Clinical Microbiology
139 at the Winnipeg Health Sciences Centre using the standard CLSI broth microdilution method^{12,13}
140 with custom-designed, in-house prepared, 96-well microtitre panels containing doubling-
141 dilutions of antimicrobial agents in cation-adjusted Mueller-Hinton broth supplemented to a final
142 concentration of 4% lysed horse blood. All isolates were tested against penicillin, ceftriaxone,
143 cefuroxime, clarithromycin, clindamycin, telithromycin, levofloxacin, moxifloxacin, linezolid,
144 trimethoprim/sulfamethoxazole, doxycycline, tigecycline, chloramphenicol and vancomycin.
145 MICs were interpreted as susceptible, intermediate or resistant using CLSI MIC breakpoints for
146 all antimicrobial agents except tigecycline for which FDA MIC breakpoints were used
147 (susceptible, ≤ 0.06 mg/L).¹⁴ MDR was defined as resistance to three or more antimicrobial
148 agents selected as antimicrobial class markers (penicillin, clarithromycin, clindamycin,
149 doxycycline, levofloxacin, trimethoprim/sulfamethoxazole and chloramphenicol). In MDR
150 calculations, penicillin resistance was defined using the CLSI breakpoint for oral penicillin V
151 (MIC, ≥ 2 mg/L).¹³ Of the 6207 invasive isolates of *S. pneumoniae* received by CARA for
152 antimicrobial susceptibility testing, complete susceptibility profiles for all 14 antimicrobial
153 agents were generated for 6001 isolates; the remaining 206 isolates failed to grow or generated
154 incomplete susceptibility profiles. The number of isolates with complete antimicrobial
155 susceptibility testing profiles per year was 1362 isolates in 2011, 1230 isolates in 2012, 1099
156 isolates in 2013, 1159 isolates in 2014 and 1151 isolates in 2015.

157 ***Statistical analysis***

158 Antimicrobial susceptibility rates between 2011 and 2015 and the associations between patient
159 demographic or isolate factors and resistance to antimicrobial agents were assessed for
160 statistically significant differences ($P < 0.05$) using the 2-tailed Chi-square test.

161

162 **Results**

163 From 2011 to 2015, small but significant increases ($P<0.05$) in percent susceptibility for
164 penicillin (by all three MIC breakpoint criteria) (1.7 – 3.2%), clindamycin (3.1% increase) and
165 ceftriaxone (by non-meningitis and meningitis MIC breakpoint criteria) (1.1 – 1.5% increase)
166 were observed for invasive isolates of *S. pneumoniae* included in the SAVE study (Table 1).
167 Susceptibility rates for all other antimicrobial agents tested remained unchanged ($P>0.05$) over
168 the five-year period/ (Table 1). In the clarithromycin subset analysis, significant differences (P
169 <0.05) in the prevalence of putative *mef*[A] (i.e., M phenotype/efflux/low-level macrolide
170 resistance; MICs of 1-32 mg/L; $n=1157$ [19.3% of all isolates]) and putative *erm*[B] (i.e., target
171 site methylation/high-level macrolide resistance; MICs of ≥ 64 mg/L; $n=240$ [4.0% of all
172 isolates]) phenotypes were not identified across the five-year period from 2011 to 2015 (data not
173 shown)¹⁵

174 The majority (71.5%; 4289/6001) of all isolates of invasive *S. pneumoniae* tested from 2011 to
175 2015 were pan-susceptible to the panel of seven antimicrobial agents used in MDR analysis (Table 2).
176 Of isolates demonstrating resistance to at least one antimicrobial agent, 62.1% (1064/1712) were
177 resistant to only a single antimicrobial agent. A MDR phenotype was demonstrated by 6.2%
178 (372/6001) of all isolates tested. The most common MDR phenotypes were concurrent resistance to
179 clarithromycin, doxycycline and clindamycin ($n=150$; 40.3% of MDR isolates), concurrent resistance
180 to clarithromycin, doxycycline, clindamycin, penicillin and trimethoprim/sulfamethoxazole ($n=110$;
181 29.6% of MDR isolates) and concurrent resistance to clarithromycin, doxycycline, clindamycin and
182 trimethoprim/sulfamethoxazole ($n=18$; 4.8% of MDR isolates) (as described elsewhere in this
183 supplement).¹⁶ The rank order of frequency of resistance to specific antimicrobial agent classes

184 among MDR isolates of invasive *S. pneumoniae* was: clarithromycin > doxycycline \approx clindamycin >
185 trimethoprim/sulfamethoxazole \approx penicillin >> chloramphenicol > levofloxacin (Table 2). The rate of
186 MDR among invasive isolates of *S. pneumoniae* decreased significantly ($P < 0.001$) from 8.5% in 2011
187 to 5.6% 2015, with the lowest rates seen during 2014 at 3.9%.

188 Rates of antimicrobial resistance in invasive isolates of *S. pneumoniae* were significantly
189 associated with patient age for chloramphenicol and clindamycin ($P < 0.05$) and approached
190 clinical significance for penicillin ($P = 0.057$) (Table 3). The penicillin resistance rates were
191 highest (4.3%) and the chloramphenicol resistance rates were lowest (0.6%) among children less
192 than 18 years of age. Clindamycin resistance rates were higher for children less than 18 years of
193 age and adults greater than 64 years of age compared to patients in the 18 to 64 year age
194 category. None of the other agents (clarithromycin, doxycycline and
195 trimethoprim/sulfamethoxazole) demonstrated a significant association with patient age. Patient
196 gender was associated with resistance to clarithromycin and approached clinical significance for
197 penicillin ($P = 0.075$). Specimen source was associated with resistance for all antimicrobial
198 agents except clarithromycin and chloramphenicol. Blood isolates generally had the lowest
199 percent resistance rates and sterile body fluids (other than blood and cerebrospinal fluid) had the
200 highest percent resistance rates. Geographic region was also associated with resistance for all
201 antimicrobial agents except clarithromycin and clindamycin, although the results approached
202 significance for these agents. Resistance to penicillin and trimethoprim/sulfamethoxazole was
203 more common among isolates from western and eastern Canada than for isolates from central
204 Canada while resistance to chloramphenicol was highest in central Canada. Resistance to
205 doxycycline was more common among isolates from central and eastern Canada than from the
206 western region. Penicillin resistance and clarithromycin resistance were associated with each

207 other and with resistance to other antimicrobial agents (doxycycline,
208 trimethoprim/sulfamethoxazole, chloramphenicol and clindamycin).

209

210 **Discussion**

211 Increases in antimicrobial resistance in *S. pneumoniae* is the result of the expansion of successful
212 clones as well as the introduction of new clonal types.¹⁷⁻²¹ Previous observations provide strong
213 evidence that the spread of penicillin-, macrolide-, trimethoprim/sulfamethoxazole-,
214 fluoroquinolone-resistant and MDR *S. pneumoniae* is often driven by the dissemination of a few
215 successful clones and that the use of non-fluoroquinolone antimicrobials (β -lactams, macrolides
216 and trimethoprim/sulfamethoxazole) may lead to resistance to all three antimicrobial classes,
217 given the propensity for these resistances to associate in clinical isolates.^{17-19,22} Given that PCV-
218 7 included serotypes that were frequently associated with non-susceptibility to penicillin and
219 other antimicrobial agents, its use facilitated changes in the epidemiology of antimicrobial
220 resistance in Canada.^{1,3}

221 In Canada, penicillin-resistant and MDR *S. pneumoniae* were rarely isolated (<5%) prior
222 to 1990.^{23,24} From the 1990s to 2000, rates of penicillin-non-susceptibility in invasive isolates of
223 pneumococci in Canada increased significantly to as high as 30% of isolates in some studies.^{23,25-}
224 ²⁹ The introduction of PCV-7 did not have an effect on the prevalence of fluoroquinolone
225 (levofloxacin, moxifloxacin) resistance in pneumococci as resistance to respiratory
226 fluoroquinolones has not been associated with clonal spread and remained at very low levels
227 (<2%) from 1998 to 2009.³⁰ However, in the same study, fluoroquinolone resistance was
228 associated with living in central or eastern Canada, patient age >64 years, respiratory tract
229 isolate, hospitals with greater numbers of beds, and isolates with penicillin MICs >1 mg/L.³⁰ In

230 the Canadian province of Alberta, from 2000 to 2006, overall, PCV-7 serotypes decreased 61%
231 accompanied by a significant decline in non-susceptibility of *S. pneumoniae* isolates to penicillin
232 from 14% in 2000 to 4.6% in 2006; non-susceptibility to erythromycin also decreased from 8.8%
233 (2000) to 5.8% (2006).³ Bettinger *et al.* showed a decrease in vaccine serotypes from 2000 to
234 2007 but no decrease in the proportion of invasive pneumococcal isolates that were penicillin-
235 resistant and ceftriaxone/cefotaxime-resistant.¹ The ABC Surveillance Program in the USA
236 determined the rates of IPD caused by antibiotic non-susceptible pneumococci for the regions
237 surveyed; rates of penicillin-non-susceptible *S. pneumoniae* dropped from a high of 6.3/100 000
238 in 1999 to 2.7/100 000 in 2004 (a drop of 57%).³¹ The greatest effect was seen in children <2
239 years of age with a decrease in penicillin-non-susceptible *S. pneumoniae* of 81%.³² Demczuk *et*
240 *al.* noted no significant changes in antimicrobial resistance rates between isolates collected
241 during 2011 and those collected in 2012 despite a concurrent decrease in relative proportions of
242 the generally resistant serotype 19A; they noted higher resistance rates for PCV-13 serotypes
243 than for non-PCV-13 serotypes for the majority of tested antimicrobial agents and that the
244 highest rates of resistance were to clarithromycin (23.3%) and penicillin using intravenous
245 meningitis breakpoints (12.4%) while resistance was lower for clindamycin (8%) and
246 trimethoprim/sulfamethoxazole (6%).⁷

247 The primary limitation of this study is the underrepresentation of British Columbia and
248 Alberta, two Canadian provinces who do not participate in the SAVE study. The regional
249 analyses may be affected by the limited representation of data from the Western provinces.

250 *S. pneumoniae* is a remarkably adaptable pathogen as demonstrated by the emergence of
251 replacement serotypes following PCV-7 and PCV-13 introduction. The isolates tested in the
252 current study were from 2011-2015, following the introduction of PCV-13 in Canada and

253 included both PCV-13 and non-PCV-13 serotypes.¹⁶ The recent report by Olarte *et al.* of
254 increasing incidence of MDR serotype 35B disease underscores the limitations of pneumococcal
255 vaccines that target the polysaccharide capsule.³² Clearly, vaccination, and replacement
256 serotypes influence the *in vitro* susceptibilities of invasive *S. pneumoniae* in Canada, and
257 elsewhere. We conclude that *in vitro* susceptibilities of invasive isolates of *S. pneumoniae*
258 increased from 2011 to 2015 for penicillin, clindamycin and ceftriaxone and that isolates with a
259 MDR phenotype decreased over the same time. Antimicrobial resistance rates were generally
260 not associated with patient gender but were associated with patient age, specimen source,
261 geographic location in Canada, and concurrent resistance to penicillin or clarithromycin for some
262 agents. Our observations are certainly the result of conjugate pneumococcal vaccine use in
263 Canada and demonstrate that vaccination may serve as one approach to lowering antimicrobial
264 resistance among invasive isolates of *S. pneumoniae*. However, appropriate use of antimicrobial
265 agents and ongoing surveillance are required to carefully monitor resistance trends by both
266 categorical results and MIC distributions. Equally important is careful analysis of surveillance
267 data in terms of factors associated with resistance and other associated trends, so that resistance
268 and susceptibility and their consequences are neither over- nor under-estimated. Such analyses
269 must be performed at national, regional, and institutional levels to guide physicians sufficiently
270 in their selection of empiric therapies for patients. To enhance the protection provided by the
271 pneumococcal conjugate vaccines, new formulations need to continue to be developed as
272 antimicrobial-resistant replacement serotypes continue to emerge.

273 **Acknowledgements**

274 We would like to thank the following Canadian Public Health Laboratory Network (CPHLN)
275 laboratories for their participation in this study: Saskatchewan Disease Control Laboratory;
276 Regina, Saskatchewan; Cadham Provincial Laboratory, Winnipeg, Manitoba; Public Health
277 Ontario Laboratories, Toronto, Ontario; Laboratoire de Santé Publique du Quebec, Ste-Anne-de-
278 Bellevue; Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia; New Brunswick
279 Regional Hospitals; Queen Elizabeth Hospital, Charlottetown, Prince Edward Island; and
280 Newfoundland Public Health Laboratory, St. John's, Newfoundland.

281

282 **Funding**

283 This work was supported, in part, by the University of Manitoba; Diagnostic Services Manitoba;
284 the National Microbiology Laboratory–Public Health Agency of Canada (NML–PHAC); Merck
285 Canada Inc.; and Pfizer Canada Inc.

286

287 **Transparency Declaration**

288 GGZ has received research grants from Merck Canada Inc. and Pfizer Canada Inc. All other
289 authors do not have conflicts to declare.

290

291 **Disclaimer**

292 The opinions expressed in this paper are those of the authors, and do not necessarily represent
293 those of Merck Canada Inc. or Pfizer Canada Inc.

294 **References**

- 295 1. Bettinger JA, Scheifele DW, Kellner JD *et al.* The effect of routine vaccination on invasive
296 pneumococcal infections in Canadian children, immunization monitoring program, active
297 2000-2007. *Vaccine* 2010; **28**: 2130-6.
- 298 2. Kuster SP, Rudnick W, Shigayeva A *et al.* Previous antibiotic exposure and antimicrobial
299 resistance in invasive pneumococcal disease: results from prospective surveillance. *Clin*
300 *Infect Dis* 2014; **59**: 944-52.
- 301 3. Tyrrell GJ, Lovgren M, Chui N *et al.* Serotypes and antimicrobial susceptibilities of invasive
302 *Streptococcus pneumoniae* pre- and post-seven valent pneumococcal conjugate vaccine
303 introduction in Alberta, Canada, 2000-2006. *Vaccine* 2009; **27**: 3553-60.
- 304 4. Poehling KA, Talbot TR, Griffin MR *et al.* Invasive pneumococcal disease among infants
305 before and after introduction of pneumococcal conjugate vaccine. *JAMA* 2006; **295**: 1668-74.
- 306 5. Hicks LA, Harrison LH, Flannery B *et al.* Incidence of pneumococcal disease due to non-
307 pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of
308 widespread PCV7 vaccination, 1998-2004. *J Infect Dis* 2007; **196**: 1346-54.
- 309 6. Adam HJ, Karlowsky JA, Nichol KA *et al.* Baseline epidemiology of *Streptococcus*
310 *pneumoniae* serotypes in Canada prior to the introduction of the 13-valent pneumococcal
311 vaccine. *Microb Drug Resist* 2012; **18**: 176-82.
- 312 7. Demczuk WHB, Martin I, Griffith A *et al.* Serotype distribution of invasive *Streptococcus*
313 *pneumoniae* in Canada after the introduction of the 13-valent pneumococcal vaccine, 2010-
314 2012. *Can J Microbiol* 2013; **59**: 778-88.
- 315 8. Public Health Agency of Canada. National Surveillance of Invasive Streptococcal Disease in
316 Canada. Annual summary 2014. Available at:

- 317 <http://www.healthycanadians.gc.ca/publications/drugs-products-medicaments-produits/2014->
318 [streptococcus/index-eng.php](http://www.healthycanadians.gc.ca/publications/drugs-products-medicaments-produits/2014-streptococcus/index-eng.php).
- 319 9. Centers for Disease Control and Prevention. 2016. Pneumococcal disease and reporting.
320 CDC, Atlanta,GA. <http://www.cdc.gov/pneumococcal/surveillance.html>.
- 321 10. National Advisory Committee on Immunization. Update on the use of 13-valent
322 pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal
323 polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older
324 – interim recommendation. 2016. www.phac-aspc.gc.ca/naci-ccni/
- 325 11. Streptococcus and STI Unit, Bacteriology and Enteric Diseases Program, National
326 Microbiology Laboratory. National Laboratory Surveillance of Invasive Streptococcal
327 Disease in Canada – Annual Summary 2014. Public Health Agency of Canada (PHAC).
328 [https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-](https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2014.html)
329 [laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2014.html](https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2014.html).
- 330 12. Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial*
331 *Susceptibility Tests for Bacteria that Grow Aerobically – Tenth Edition: Approved Standard*
332 *M07-A10*. Wayne, PA, USA, 2015.
- 333 13. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial*
334 *Susceptibility Testing: Twenty-Seventh Edition. M100*. Wayne, PA, USA, 2017.
- 335 14. Pfizer, Inc. Tygacil. FDA product information. Pfizer, Inc., Collegeville, PA. 2016.
336 <https://www.pfizer.com>.
- 337 15. Wierzbowski AK, Karlowsky JA, Adam HJ *et al*. Evolution and molecular characterization
338 of macrolide-resistant *Streptococcus pneumoniae* in Canada between 1998 and 2008. *J*
339 *Antimicrob Chemother* 2014; **69**: 59-66.

- 340 16. Adam HJ, Golden AR, Karlowsky JA *et al.* Analysis of multi-drug resistance in the
341 predominant *Streptococcus pneumoniae* serotypes in Canada: the SAVE study, 2011-2015.
342 Journal of Antimicrobial Chemotherapy 2017, current supplement paper.
- 343 17. Nichol KA, Adam HJ, Karlowsky JA *et al.* Increasing genetic relatedness of ciprofloxacin-
344 resistant *Streptococcus pneumoniae* isolated in Canada from 1997 to 2005. *Antimicrob*
345 *Agents Chemother* 2008; **52**: 1190-4.
- 346 18. Klugman KP. The successful clone: the vector of dissemination of resistance in
347 *Streptococcus pneumoniae*. *J Antimicrob Chemother* 2002; **50(Suppl S2)**: 1-5.
- 348 19. McGee L, McDougal L, Zhou J *et al.* Nomenclature of major antimicrobial-resistant clones
349 of *Streptococcus pneumoniae* defined by the Pneumococcal Molecular Epidemiology
350 Network. *J Clin Microbiol* 2001; **39**: 2565-71.
- 351 20. de la Campa AG, Balsalobre L, Ardanuy C *et al.* Fluoroquinolone resistance in penicillin-
352 resistant *Streptococcus pneumoniae* clones, Spain. *Emerg Infect Dis* 2004; **10**: 1751-9.
- 353 21. Greenberg D, Speert DP, Mahenthiralingam E *et al.* Emergence of penicillin-nonsusceptible
354 *Streptococcus pneumoniae* invasive clones in Canada. *J Clin Microbiol* 2002; **40**: 68-74.
- 355 22. Golden AR, Adam HJ, Gilmour MW *et al.* Assessment of multidrug resistance, clonality and
356 virulence in non-PCV-13 *Streptococcus pneumoniae* serotypes in Canada, 2011-13. *J*
357 *Antimicrob Chemother* 2015; **70**: 1960-4.
- 358 23. Simor AE, Louie M, Low DE. Canadian national survey of prevalence of antimicrobial
359 resistance among clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents*
360 *Chemother* 1996; **40**: 2190-3.

- 361 24. Jetté LP, Lamothe F. Surveillance of invasive *Streptococcus pneumoniae* infection in
362 Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and
363 clinical characteristics. *J Clin Microbiol* 1989; **27**: 1-5.
- 364 25. Scheifele D, Halperin S, Pelletier L *et al.* Reduced susceptibility to penicillin among
365 pneumococci causing invasive infection in children – Canada, 1991 to 1998. *Can J Infect Dis*
366 2001; **12**: 241-6.
- 367 26. Lovgren M, Spika JS, Talbot JA. Invasive *Streptococcus pneumoniae* infections: serotype
368 distribution and antimicrobial resistance in Canada, 1992-1995. *Can Med Assoc J* 1998; **158**:
369 327-31.
- 370 27. Davidson RJ, Melano R, Canadian Invasive Pneumococcal Surveillance Group, Forward KR
371 Antimicrobial resistance among invasive isolates of *Streptococcus pneumoniae* collected
372 across Canada. *Diagn Microbiol Infect Dis* 2007; **59**: 75-80.
- 373 28. Zhanel GG, Palatnick L, Nichol KA *et al.* Antimicrobial resistance in respiratory tract
374 *Streptococcus pneumoniae* isolates: results of the Canadian respiratory organism
375 susceptibility study, 1997-2002. *Antimicrob Agents Chemother* 2003; **47**: 1867–74.
- 376 29. Pfaller MA, Jones RN, Doern GV *et al.* Bacterial pathogens isolated from patients with
377 bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns
378 from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).
379 *Antimicrob Agents Chemother* 1998; **42**: 1762-70.
- 380 30. Patel SN, McGeer A, Melano R *et al.* Susceptibility of *Streptococcus pneumoniae* to
381 fluoroquinolones in Canada. *Antimicrob Agents Chemother* 2011; **55**: 3703-8.

- 382 31. Kyaw MH, Lynfield R, Schaffner W *et al.* Effect of introduction of the pneumococcal
383 conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Engl J Med* 2006; **354**:
384 1455-63.
- 385 32. Olarte L, Kaplan SL, Barson WJ *et al.* Emergence of multidrug-resistant pneumococcal
386 serotype 35B among children in the United States. *J Clin Microbiol* 2017; **55**: 724-34.

Table 1. Annual antimicrobial susceptibility testing results for 14 antimicrobial agents tested against invasive isolates of *S. pneumoniae* as part of the SAVE study from 2011 to 2015

Antimicrobial agent	Year ^a					<i>P</i> ^b
	2011	2012	2013	2014	2015	
	Percent susceptible/percent resistant/MIC ₉₀ (mg/L)					
Penicillin (IV, nonmeningitis)	97.3/0/0.12	98.1/0.1/0.12	99.0/0.1/0.12	99.1/0.1/0.06	99.0/0/0.12	0.001
Penicillin (IV, meningitis)	86.3/13.7/0.12	89.1/10.9/0.12	89.9/10.1/0.12	91.0/9.0/0.06	89.5/10.5/0.12	0.017
Penicillin (oral, penicillin V)	86.3/4.2/0.12	89.1/3.1/0.12	89.9/3.5/0.12	91.0/2.1/0.06	89.5/3.0/0.12	0.017
Ceftriaxone (nonmeningitis)	98.6/0.2/≤0.12	99.2/0.2/≤0.12	99.3/0.2/≤0.12	99.8/0.1/≤0.12	99.7/0/≤0.12	0.002
Ceftriaxone (meningitis)	95.8/1.4/≤0.12	96.5/0.8/≤0.12	96.5/0.7/≤0.12	97.6/0.2/≤0.12	97.3/0.3/≤0.12	0.050
Cefuroxime (parenteral)	94.7/5.1/≤0.25	95.7/4.1/≤0.25	94.2/4.9/≤0.25	94.7/5.1/≤0.25	94.0/5.5/≤0.25	0.487
Cefuroxime (oral)	94.9/4.8/≤0.25	95.9/3.7/≤0.25	95.1/3.7/≤0.25	94.9/3.7/≤0.25	94.5/4.1/≤0.25	0.721
Clarithromycin	76.8/22.5/8	74.2/23.7/4	73.1/25.1/4	76.6/22.2/2	74.9/23.1/2	0.282
Clindamycin	90.7/8.9/≤0.12	93.6/6.3/≤0.12	93.3/5.8/≤0.12	94.9/4.6/≤0.12	93.8/6.0/≤0.12	0.004
Telithromycin	99.9/0/0.12	100/0/0.12	100/0/0.12	100/0/0.12	100/0/0.12	1
Levofloxacin	99.6/0.4/1	99.3/0.6/1	99.4/0.5/1	99.0/0.9/1	99.7/0.3/1	0.762
Moxifloxacin	99.6/0.2/0.25	99.3/0.4/0.25	99.5/0/0.25	99.1/0.8/0.25	99.7/0.1/0.12	1
Linezolid	100/0/1	100/0/2	100/0/2	100/0/1	100/0/1	1
Trimethoprim/sulfamethoxazole	87.2/5.8/1	88.1/5.7/1	86.2/7.6/1	89.3/5.9/1	87.4/6.3/1	0.904
Doxycycline	88.5/10.9/2	89.2/10.2/1	89.4/9.8/0.5	91.1/8.0/≤0.25	90.2/8.7/≤0.25	0.175
Tigecycline	100/0/0.03	100/0/0.03	100/0/0.03	100/0/0.03	100/0/0.03	1
Chloramphenicol	99.0/1.0/4	97.7/2.3/4	99.0/1.0/4	96.8/3.2/4	99.0/1.0/4	1
Vancomycin	100/0/0.5	100/0/0.5	100/0/0.25	100/0/0.25	100/0/0.25	1

^a A total of 6001 isolates of *S. pneumoniae* were available for antimicrobial susceptibility testing from 2001 to 2015. The number of isolates tested per year was 1362 isolates in 2011, 1230 isolates in 2012, 1099 isolates in 2013, 1159 isolates in 2014, and 1151 isolates in 2015.

^b *P* values generated by comparing antimicrobial susceptibility rates for 2011 versus 2015.

Table 2. Resistance to one or more antimicrobial agents among invasive isolates of *S. pneumoniae* in the SAVE study from 2011 to 2015 (cumulative data)

Number of antimicrobial agents to which isolates were resistant ^a	% of total isolates tested (<i>n</i>) ^b	Percent of isolates (<i>n</i>) resistant to the indicated antimicrobial agent						
		Penicillin	Clarithromycin	Clindamycin	Doxycycline	Levofloxacin	SXT ^c	Chloramphenicol
0	71.5 (4289)	-	-	-	-	-	-	-
1	17.7 (1064)	0.6 (6)	77.2 (821)	0.3 (3)	8.5 (90)	2.0 (21)	9.6 (102)	2.0 (21)
2	4.6 (276)	6.2 (17)	76.1 (210)	18.5 (51)	47.5 (131)	1.4 (4)	34.1 (94)	16.3 (45)
3 ^{d,e}	3.1 (184)	9.2 (17)	96.7 (178)	84.8 (156)	91.3 (168)	1.1 (2)	12.5 (23)	4.3 (8)
4 ^{d,e}	1.1 (64)	46.9 (30)	100 (64)	79.7 (51)	96.9 (62)	4.7 (3)	51.6 (33)	20.3 (13)
5 ^{d,e}	1.9 (115)	98.3 (113)	100 (115)	99.1 (114)	100 (115)	0.9 (1)	97.4 (112)	4.3 (5)
6 ^{d,e}	0.1 (8)	100 (8)	100 (8)	100 (8)	100 (8)	12.5 (1)	100 (8)	87.5 (7)
7 ^{d,e}	<0.1 (1)	100 (1)	100 (1)	100 (1)	100 (1)	100 (1)	100 (1)	100 (1)

^a The antimicrobial agents used in this analysis were selected as antimicrobial class markers: penicillin (oral MIC breakpoints), clarithromycin, clindamycin, doxycycline, levofloxacin, trimethoprim/sulfamethoxazole, and chloramphenicol.

^b A total of 6001 isolates of *S. pneumoniae* were available for antimicrobial susceptibility testing from 2001 to 2015.

^c SXT, trimethoprim/sulfamethoxazole.

^d MDR was defined as concurrent resistance to three or more of the seven antimicrobial classes analyzed; 6.2% (372/6001) of all isolates from 2011 to 2015 were MDR.

^e The percent prevalence of MDR isolates (*n*/total *n*) by year was 8.5% (116/1362) in 2011, 6.8 % (83/1230) in 2012, 5.8% (64/1099) in 2013, 3.9% (45/1159) in 2014, 5.6% (64/1151) in 2015 (*P* <0.001).

Table 3. Relative associations between resistance to six^a antimicrobial agents and patient demographic/isolate factors among invasive isolates of *S. pneumoniae* in the SAVE study from 2011 to 2015 (cumulative data)

Patient demographic/isolate factor	n of isolates associated with risk factor	Penicillin		Clarithromycin		Doxycycline		SXT ^a		Chloramphenicol		Clindamycin	
		n (%) of resistant isolates	P ^b	n (%) of resistant isolates	P								
All isolates	6001	192 (3.2%)	–	1397 (23.3%)	–	575 (9.6%)	–	373 (6.2%)	–	100 (1.7%)	–	384 (6.4%)	–
Patient age, years ^c			0.057		0.307		0.101		0.335		0.026		0.004
<18	851	37 (4.3%)		208 (24.4%)		81 (9.5%)		62 (7.3%)		5 (0.6%)		65 (7.6%)	
18-64	2788	76 (2.7%)		627 (22.5%)		245 (8.8%)		165 (5.9%)		51 (1.8%)		148 (5.3%)	
>64	2231	73 (3.3%)		537 (24.1%)		236 (10.6%)		135 (6.1%)		43 (1.9%)		164 (7.4%)	
Patient gender ^d			0.075		0.041		0.669		0.432		0.627		0.775
Female	2660	97 (3.6%)		660 (24.8%)		262 (9.8%)		158 (5.9%)		47 (1.8%)		175 (6.6%)	
Male	3121	88 (2.8%)		703 (22.5%)		297 (9.5%)		201 (6.4%)		50 (1.6%)		199 (6.4%)	
Invasive specimen source			<0.001		0.154		<0.001		0.004		0.950		<0.001
Blood	5448	155 (2.8%)		1257 (23.1%)		498 (9.1%)		322 (5.9%)		90 (1.7%)		326 (6.0%)	
Cerebrospinal fluid	235	9 (3.8%)		52 (22.1%)		27 (11.5%)		18 (7.7%)		4 (1.7%)		22 (9.4%)	
Other sterile body fluids ^e	318	28 (8.8%)		88 (27.7%)		50 (15.7%)		33 (10.4%)		6 (1.9%)		36 (11.3%)	
Geographic region ^f			<0.001		0.051		<0.001		0.003		<0.001		0.077
Western Canada	1321	53 (4.0%)		336 (25.4%)		89 (6.7%)		102 (7.7%)		12 (0.9%)		67 (5.1%)	
Central Canada	3952	102 (2.6%)		883 (22.3%)		411 (10.4%)		215 (5.4%)		84 (2.1%)		270 (6.8%)	
Eastern Canada	728	37 (5.1%)		178 (24.5%)		75 (10.3%)		56 (7.7%)		4 (0.5%)		47 (6.5%)	
Penicillin MIC interpretative category ^g			–		<0.001		<0.001		<0.001		<0.001		<0.001
Susceptible (≤ 0.06 mg/L)	5345	–		991 (18.5%)		204 (3.8%)		131 (2.5%)		85 (1.6%)		115 (2.2%)	
Intermediate (0.12-1 mg/L)	464	–		233 (50.2%)		213 (45.9%)		86 (18.5%)		4 (0.9%)		130 (28.0%)	
Resistant (≥ 2 mg/L)	192	–		173 (90.1%)		158 (82.3%)		156 (81.2%)		11 (5.7%)		139 (72.4%)	
Clarithromycin MIC interpretative category			<0.001		–		<0.001		<0.001		<0.001		<0.001
Susceptible (≤ 0.25 mg/L)	4512	16 (0.4%)		–		124 (2.7%)		119 (2.6%)		59 (1.3%)		4 (0.1%)	
Intermediate (0.5 mg/L)	92	3 (3.3%)		–		28 (30.4%)		10 (10.9%)		1 (1.1%)		5 (5.4%)	
Resistant (≥ 1 mg/L)	1397	173 (12.4%)		–		423 (30.3%)		244 (17.5%)		40 (2.9%)		375 (26.8%)	

^a SXT, trimethoprim/sulfamethoxazole.

^b The Chi-square test identified significant differences between individual patient demographic/isolate factors within a group of factors but does not specify the identity of the difference within the group of factors.

^c There were 131 isolates with unknown patient age.

^d There were 220 isolates with unknown patient gender.

^e Other sterile body fluids were comprised of pleural fluid ($n=123$), synovial fluid ($n=38$), peritoneal fluid ($n=12$), pericardial fluid ($n=4$), abscess ($n=3$), other sterile site/source not given ($n=138$).

^f Western Canada included isolates from Manitoba and Saskatchewan, Central Canada included isolates from Ontario and Quebec, and Eastern Canada included isolates from Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador.

^g Penicillin (oral penicillin V) MIC breakpoints were used.